Compare Stocks: GRAL, EXEL, BMRN, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.70	$49.26 ▼ $70.98	$12.52B	0.24	2.32 million shs	1.10 million shs
EXEL Exelixis	$54.45 -1.5%	$54.57	$33.76 ▼ $57.57	$13.49B	0.44	2.68 million shs	1.49 million shs
GRAL GRAIL	$80.00 -3.0%	$70.93	$30.82 ▼ $118.84	$3.57B	3.24	777,008 shs	658,502 shs
HALO Halozyme Therapeutics	$105.35 -1.5%	$87.01	$61.22 ▼ $109.66	$11.96B	0.85	2.37 million shs	1.68 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.95%	-3.04%	+5.38%	+12.88%	+10.25%
EXEL Exelixis	-1.47%	+0.68%	-1.47%	+7.86%	+41.39%
GRAL GRAIL	-3.03%	+0.58%	+26.10%	+11.61%	+137.88%
HALO Halozyme Therapeutics	-1.47%	-2.61%	+26.50%	+58.33%	+43.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$64.67 -0.9%	$61.70	$49.26 ▼ $70.98	$12.52B	0.24	2.32 million shs	1.10 million shs
EXEL Exelixis	$54.45 -1.5%	$54.57	$33.76 ▼ $57.57	$13.49B	0.44	2.68 million shs	1.49 million shs
GRAL GRAIL	$80.00 -3.0%	$70.93	$30.82 ▼ $118.84	$3.57B	3.24	777,008 shs	658,502 shs
HALO Halozyme Therapeutics	$105.35 -1.5%	$87.01	$61.22 ▼ $109.66	$11.96B	0.85	2.37 million shs	1.68 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-0.95%	-3.04%	+5.38%	+12.88%	+10.25%
EXEL Exelixis	-1.47%	+0.68%	-1.47%	+7.86%	+41.39%
GRAL GRAIL	-3.03%	+0.58%	+26.10%	+11.61%	+137.88%
HALO Halozyme Therapeutics	-1.47%	-2.61%	+26.50%	+58.33%	+43.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.79	37.30% Upside
EXEL Exelixis	2.30	Hold	$50.07	-8.05% Downside
GRAL GRAIL	2.30	Hold	$67.78	-15.28% Downside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-13.43% Downside

Current Analyst Ratings Breakdown

Latest GRAL, EXEL, BMRN, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00
8/14/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.89	$2.85 per share	22.66	$32.66 per share	1.98
EXEL Exelixis	$2.32B	5.82	$3.03 per share	17.99	$7.44 per share	7.32
GRAL GRAIL	$147.17M	24.28	N/A	N/A	$56.93 per share	1.41
HALO Halozyme Therapeutics	$1.40B	8.56	$4.77 per share	22.08	$1.26 per share	83.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	174.78	11.98	0.46	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.12	14.68	1.62	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	31.45	11.38	0.42	24.86%	260.98%	23.91%	11/2/2026 (Estimated)

Latest GRAL, EXEL, BMRN, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
GRAL GRAIL	N/A	10.95	10.95
HALO Halozyme Therapeutics	13.50	2.71	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
GRAL GRAIL	N/A
HALO Halozyme Therapeutics	97.79%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
GRAL GRAIL	1.83%
HALO Halozyme Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
GRAL GRAIL	1,360	44.67 million	43.85 million	Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable

GRAL, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

Royal London Asset Management Ltd. Has $141.73 Million Holdings in Halozyme Therapeutics, Inc. $HALO

August 29 at 7:12 AM | marketbeat.com

Livforsakringsbolaget Skandia Omsesidigt Invests $9.71 Million in Halozyme Therapeutics, Inc. $HALO

August 29 at 6:25 AM | marketbeat.com

Hsbc Holdings PLC Purchases New Holdings in Halozyme Therapeutics, Inc. $HALO

August 29 at 5:43 AM | marketbeat.com

174,061 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by The Manufacturers Life Insurance Company

August 29 at 5:30 AM | marketbeat.com

Tight action in HALO stock sets up heavenly gains

August 28 at 7:04 PM | msn.com

Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice

August 28 at 1:01 PM | zacks.com

146,113 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Harvey Capital Management Inc.

August 28 at 6:08 AM | marketbeat.com

Centaurus Financial Inc. Invests $1.87 Million in Halozyme Therapeutics, Inc. $HALO

August 28 at 4:23 AM | marketbeat.com

14,500 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Coastal Bridge Advisors LLC

August 28 at 4:16 AM | marketbeat.com

1,072,439 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by Caisse de depot et placement du Quebec

August 28 at 4:00 AM | marketbeat.com

5 Value Stocks to Buy Right Now as Inflation Remains Sticky

August 27 at 12:10 PM | zacks.com

Redwood Investment Management LLC Invests $2.20 Million in Halozyme Therapeutics, Inc. $HALO

August 27 at 6:32 AM | marketbeat.com

Panoramic Capital LLC Takes Position in Halozyme Therapeutics, Inc. $HALO

August 27 at 6:07 AM | marketbeat.com

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

August 27 at 5:31 AM | zacks.com

Jupiter Topco LLC Takes $105.57 Million Position in Halozyme Therapeutics, Inc. $HALO

August 27 at 5:29 AM | marketbeat.com

Sanctuary Advisors LLC Buys Shares of 19,611 Halozyme Therapeutics, Inc. $HALO

August 27 at 5:04 AM | marketbeat.com

Deutsche Bank AG Invests $3.60 Million in Halozyme Therapeutics, Inc. $HALO

August 27 at 3:35 AM | marketbeat.com

Bank of New York Mellon Corp Invests $62.79 Million in Halozyme Therapeutics, Inc. $HALO

August 27 at 3:29 AM | marketbeat.com

Halozyme Therapeutics Inc 1HALO

August 26 at 8:18 PM | morningstar.comM

5 Biotech Stocks Worth Adding to Your Portfolio Now

August 26 at 11:20 AM | zacks.com

Unpacking Q2 earnings: Novavax (NASDAQ:NVAX) in the context of other therapeutics stocks

August 26 at 9:41 AM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL, EXEL, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$64.67 -0.62 (-0.95%)

As of 08/28/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$54.45 -0.81 (-1.47%)

As of 08/28/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

GRAIL NASDAQ:GRAL

$80.00 -2.50 (-3.03%)

As of 08/28/2026 04:00 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Halozyme Therapeutics NASDAQ:HALO

$105.35 -1.57 (-1.47%)

As of 08/28/2026 04:00 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRAL, EXEL, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRAL, EXEL, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRAL, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL, EXEL, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

GRAIL NASDAQ:GRAL

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRAL, EXEL, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRAL, EXEL, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRAL, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL, EXEL, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

GRAIL NASDAQ:GRAL

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools